Stocks · News reference

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Aug 17, 2026, 5:45 PMVandana Singh

Mesoblast finished patient dosing in its Phase 3 trial for a cellular back pain treatment, targeting a market worth over $10 billion.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 24, 2026, 11:06 AMBenzinga Newsdesk
Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil
The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities. This assay will be
MESO
BenzingaAug 27, 2026, 5:25 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39
Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.
MESO
BenzingaAug 27, 2026, 2:34 PMBenzinga Newsdesk
Mesoblast shares are trading higher after the company reported better-than-expected FY sales results.
MESO
BenzingaAug 27, 2026, 1:00 PMBenzinga Newsdesk
Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate
Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same
MESO